Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35210560 | 0.87 | ROCK1 (0.34) | ROCK1CA1CA2CA9 | |
| SCHEMBL35210583 | 0.86 | NR4A2 (0.39) | ROCK1KMT2A | |
| SCHEMBL1622731 | 0.81 | NR4A2 (0.38) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL30633682 | 0.78 | KDM4E (0.40) | ROCK1 | |
| SCHEMBL35210704 | 0.77 | NOTUM (0.37) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL26630556 | 0.76 | ROCK1 (0.38) | ROCK1CA12CA1CA2CA9 | |
| SCHEMBL30673248 | 0.74 | ROCK1 (0.37) | ROCK1CA12CA1CA2CA9 | |
| SCHEMBL27433795 | 0.74 | ROCK1 (0.37) | ROCK1CA12CA1CA2CA9 | |
| SCHEMBL26928552 | 0.74 | ROCK1 (0.37) | ROCK1CA12CA1CA2CA9 | |
| SCHEMBL515152 | 0.74 | ROCK1 (0.40) | ROCK1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | CDK4, CCNA1, CCNO | ROCK1 1239/4885CA12 4070/4885CA1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.